X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DR. REDDYS LAB - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DR. REDDYS LAB PFIZER/
DR. REDDYS LAB
 
P/E (TTM) x 24.2 27.3 88.7% View Chart
P/BV x 3.8 2.8 136.9% View Chart
Dividend Yield % 0.8 1.0 83.5%  

Financials

 PFIZER   DR. REDDYS LAB
EQUITY SHARE DATA
    PFIZER
Mar-16
DR. REDDYS LAB
Mar-16
PFIZER/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs2,7244,383 62.1%   
Low Rs1,6112,750 58.6%   
Sales per share (Unadj.) Rs440.9920.1 47.9%  
Earnings per share (Unadj.) Rs48.7126.1 38.6%  
Cash flow per share (Unadj.) Rs75.8183.0 41.4%  
Dividends per share (Unadj.) Rs15.0020.00 75.0%  
Dividend yield (eoy) %0.70.6 123.4%  
Book value per share (Unadj.) Rs462.9685.8 67.5%  
Shares outstanding (eoy) m45.75170.61 26.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.93.9 126.8%   
Avg P/E ratio x44.528.3 157.4%  
P/CF ratio (eoy) x28.619.5 146.8%  
Price / Book Value ratio x4.75.2 90.0%  
Dividend payout %30.815.9 194.2%   
Avg Mkt Cap Rs m99,163608,481 16.3%   
No. of employees `0002.921.7 13.3%   
Total wages/salary Rs m2,75831,874 8.7%   
Avg. sales/employee Rs Th6,981.77,244.4 96.4%   
Avg. wages/employee Rs Th954.51,470.9 64.9%   
Avg. net profit/employee Rs Th771.1992.8 77.7%   
INCOME DATA
Net Sales Rs m20,170156,978 12.8%  
Other income Rs m8572,693 31.8%   
Total revenues Rs m21,028159,671 13.2%   
Gross profit Rs m4,31034,587 12.5%  
Depreciation Rs m1,2399,705 12.8%   
Interest Rs m5824 0.6%   
Profit before tax Rs m3,92326,751 14.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7945,237 34.3%   
Profit after tax Rs m2,22821,514 10.4%  
Gross profit margin %21.422.0 97.0%  
Effective tax rate %45.719.6 233.6%   
Net profit margin %11.013.7 80.6%  
BALANCE SHEET DATA
Current assets Rs m16,299118,201 13.8%   
Current liabilities Rs m7,59468,368 11.1%   
Net working cap to sales %43.231.7 135.9%  
Current ratio x2.11.7 124.1%  
Inventory Days Days6560 108.8%  
Debtors Days Days2697 26.6%  
Net fixed assets Rs m8,62272,265 11.9%   
Share capital Rs m458853 53.6%   
"Free" reserves Rs m20,722111,548 18.6%   
Net worth Rs m21,180117,009 18.1%   
Long term debt Rs m2510,690 0.2%   
Total assets Rs m29,137200,104 14.6%  
Interest coverage x755.533.5 2,257.5%   
Debt to equity ratio x00.1 1.3%  
Sales to assets ratio x0.70.8 88.2%   
Return on assets %7.711.2 68.7%  
Return on equity %10.518.4 57.2%  
Return on capital %19.021.6 88.0%  
Exports to sales %0.146.3 0.1%   
Imports to sales %17.59.0 195.3%   
Exports (fob) Rs m1272,618 0.0%   
Imports (cif) Rs m3,52614,050 25.1%   
Fx inflow Rs m5275,405 0.1%   
Fx outflow Rs m14027,115 0.5%   
Net fx Rs m-8848,290 -0.2%   
CASH FLOW
From Operations Rs m3,43640,476 8.5%  
From Investments Rs m-6,991-19,421 36.0%  
From Financial Activity Rs m-619-17,009 3.6%  
Net Cashflow Rs m-4,1744,046 -103.2%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 5.4 138.9%  
FIIs % 4.9 35.3 13.9%  
ADR/GDR % 0.0 18.5 -  
Free float % 23.7 15.3 154.9%  
Shareholders   85,207 75,885 112.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 18, 2017 (Close)

TRACK PFIZER

PFIZER - SHASUN PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS